### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended that oral deferasirox be transferred to the core list of the EML and EMLc for use in the treatment of transfusional iron overload in patients with thalassaemia syndromes, sickle cell disease and other chronic anaemias, with a square box listing specifying oral deferiprone as a therapeutic alternative. The Committee also recommended that intravenous deferoxamine should remain listed on the complementary list of the EML and EMLc for these indications, and the square box associated with the current listing be removed. The Committee accepted that the comparative efficacy and safety of deferiprone, deferoxamine and deferasirox were generally similar, and that orally administered treatments may be preferred options. The Committee recognized the value in having multiple iron chelating agents included on the Model Lists to enable countries to make appropriate national selection decisions taking into consideration relevant contextual factors.